Ansuvimab-zykl (Ebanga), a human monoclonal antibody, has been approved to treat Zaire ebolavirus (Ebolavirus) infection.The most common adverse effects of the drug are fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; these are also common symptoms of Ebolavirus infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000742484.81331.b2 | DOI Listing |
Publication Analysis
Top Keywords
monoclonal antibody
8
antibody approved
8
approved treat
8
treat ebola
4
ebola ansuvimab-zykl
4
ansuvimab-zykl ebanga
4
ebanga human
4
human monoclonal
4
treat zaire
4
zaire ebolavirus
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!